Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
Condition: Head and Neck Cancer Interventions: Drug: Nivolumab; Drug: Cisplatin; Drug: Docetaxel; Radiation: Radioimmunotherapy Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | Hypopharyngeal Cancer | Laryngeal Cancer | Research | Taxotere